CHP
CNCE

Cable Hill Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Cable Hill Partners’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-500
Closed -$8K – 903
2018
Q2 		$8K Buy
+500
New +$9.71K ﹤0.01% 547

Other funds holding CNCE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cable Hill Partners's CNCE Position: Q3 2018 in Review

Cable Hill Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q3 2018, closing a stake of 500 shares — an estimated $8K sold.

Cable Hill Partners first reported a position in CNCE in Q2 2018 and held it in 1 quarter. The position peaked at $8K in Q2 2018. 111 funds tracked by Wall St. Rank hold CNCE as of Q3 2018.

  • Cable Hill Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Cable Hill Partners sold 500 Concert Pharmaceuticals, Inc. shares in Q3 2018, an estimated $8K.
  • Cable Hill Partners first reported a position in Concert Pharmaceuticals, Inc. in Q2 2018 and held it in 1 quarter.
  • Cable Hill Partners's Concert Pharmaceuticals, Inc. position peaked at $8K in Q2 2018.
  • 111 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q3 2018.

Based on Cable Hill Partners's 13F filing for Q3 2018, filed 14 Nov 2018.